U.S. Army Captain Michael Kelvington, commander of the Battle company, 1-508 Parachute Infantry battalion, 4th Brigade Combat Team, 82nd Airborne Division, bows next to remains of Gulam Dostager, a member of Afghan Local Police who was killed in the blast of an Improvised Explosive Device (IED) during the joint Tor Janda (Black Flag in Pashtu) operation, in Zahri district of Kandahar province, southern Afghanistan May 25, 2012.  REUTERS/Shamil Zhumatov  (AFGHANISTAN - Tags: MILITARY CIVIL UNREST CONFLICT TPX IMAGES OF THE DAY)

Reuters Photojournalism

Our day's top images, in-depth photo essays and offbeat slices of life. See the best of Reuters photography.  See more | Photo caption 

Members of the U.S. Navy Blue Angels fly over the World Trade Center in lower Manhattan as part of the 25th annual Fleet Week celebration in New York, May 23, 2012.  REUTERS/Eduardo Munoz (UNITED STATES - Tags: MILITARY ANNIVERSARY TPX IMAGES OF THE DAY)

Fleet Week

The U.S. Navy takes Manhattan for a week.  Slideshow 

Photo

The SpaceX mission

A privately owned unmanned rocket blasts off on a mission to be the first commercial flight to the International Space Station.  Slideshow 

Factbox: ScriptPad

Related Topics

BOULDER | Fri Nov 19, 2010 9:01am EST

BOULDER (Reuters) - Imagine your health hinging on your doctor's penmanship. That's a scenario ScriptPad is trying to avoid by offering physicians the ability to enter prescriptions directly into their iPhone or iPad.

**********************

Company: ScriptPad, has developed an app that allows doctors to write electronic prescriptions on iPads and iPhones.

Location: Boulder, CO

Founded: 2010

Founders: Shane Taylor and Liam Davis-Mead

Website: www.scriptpad.net

Initial startup costs/investment: Received $12,000 through TechStars and are looking to raise an additional $300,000 seed round from angel investors.

Number of employees: 3

Biggest challenge to growing the company: Getting older physicians to change over to e-prescriptions instead of using paper pads.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.